Nanomedicine News

RSS

T2 Magnetic Resonance Nanotechnology Solution Rapidly Detects Sepsis-Causing Fungus

T2 Biosystems, a company developing direct detection products enabling superior diagnostics, today announced the publication of research supporting the Company's flagship diagnostic test, T2Candida®, in Science Translational Medicine.

25 Apr 2013

NanoViricides to Discuss its Broad Drug Pipeline at BIO International Convention

NanoViricides, Inc. (the "Company") announced today that its President, Dr. Anil Diwan, will present an overview of the company at the 2013 BIO International Convention being held at the McCormick Center in Chicago, Illinois from April 22 to 25, 2013 (http://convention.bio.org/).

From NanoViricides, Inc 25 Apr 2013

Intranasal Delivery of Novel Nanoparticles May Help Treat Parkinson's Disease

Researchers at Northeastern University in Boston have developed a gene therapy approach that may one day stop Parkinson's disease (PD) in it tracks, preventing disease progression and reversing its symptoms. The novelty of the approach lies in the nasal route of administration and nanoparticles containing a gene capable of rescuing dying neurons in the brain.

24 Apr 2013

Covaris Debuts High Performance Formulation Processing System for Producing Nanosuspensions

Covaris, Inc. today announced the introduction of the FS220-M High Performance Formulation Processing System.

24 Apr 2013

ABL Reports Positive Results from Human-Ingestion Safety Study on Nano-Silver Particle Supplement

American Biotech Labs (ABL) has just released what is believed to be the first ever human-ingestion safety study on both a silver supplement, and also a nano-particle. The published abstract for the study states that ingestion of the patented ABL nano-silver particle showed no negative effects on any tested system in the body.

24 Apr 2013

BIND and AstraZeneca Partner to Commercialize Programmable Cancer Nanomedicine

BIND Therapeutics and AstraZeneca announced today that they have entered into a strategic collaboration to develop and commercialize an AccurinTM, a targeted and programmable cancer nanomedicine from BIND’s Medicinal Nanoengineering platform, based on a molecularly targeted kinase inhibitor developed and owned by AstraZeneca.

23 Apr 2013

NanoViricides’ Oral and Injectable FluCide Drug Candidates May be Effective against Novel H7N9 Strain

NanoViricides, Inc. (the "Company") said it anticipates that the oral and injectable FluCide™ drug candidates would be effective against the novel H7N9 strain that has caused human fatalities in China in recent months.

From NanoViricides, Inc 23 Apr 2013

Nanotechnology the Focus of UCLA Annual Tech Forum

The UCLA Henry Samueli School of Engineering and Applied Science presents its annual Tech Forum. This year's free daylong conference, "The Future of Engineering Research in the United States," brings together many of the top engineering minds in California.

From University of California, Los Angeles 22 Apr 2013

First-Generation Nano-Impedance Biosensor Released by Pharmaco-Kinesis

Pharmaco-Kinesis Corporation (PKC), developer of a pre-commercialized smart implantable pump for localized cancer-fighting drug delivery, today announced its first commercialized offering, the first-generation Nano-Impedance Biosensor (NIB).

20 Apr 2013

Nanoparticles with Separate Compartments Can Carry Different Drugs to the Same Location

Spongelike nanoparticles whose pores can be filled with drugs offer the promise of drug delivery to specific targets in the body, avoiding unpleasant side effects. Cornell researchers have now created nanoparticles with separate compartments that could carry two or more different drugs to the same location, with precise control over the amounts.

20 Apr 2013